1. Home
  2. ADPT vs TPC Comparison

ADPT vs TPC Comparison

Compare ADPT & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • TPC
  • Stock Information
  • Founded
  • ADPT 2009
  • TPC 1894
  • Country
  • ADPT United States
  • TPC United States
  • Employees
  • ADPT N/A
  • TPC N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • ADPT Health Care
  • TPC Consumer Discretionary
  • Exchange
  • ADPT Nasdaq
  • TPC Nasdaq
  • Market Cap
  • ADPT 1.1B
  • TPC 1.0B
  • IPO Year
  • ADPT 2019
  • TPC N/A
  • Fundamental
  • Price
  • ADPT $9.03
  • TPC $32.74
  • Analyst Decision
  • ADPT Buy
  • TPC Strong Buy
  • Analyst Count
  • ADPT 6
  • TPC 2
  • Target Price
  • ADPT $9.83
  • TPC $39.50
  • AVG Volume (30 Days)
  • ADPT 3.0M
  • TPC 691.5K
  • Earning Date
  • ADPT 05-01-2025
  • TPC 05-07-2025
  • Dividend Yield
  • ADPT N/A
  • TPC N/A
  • EPS Growth
  • ADPT N/A
  • TPC N/A
  • EPS
  • ADPT N/A
  • TPC N/A
  • Revenue
  • ADPT $189,527,000.00
  • TPC $4,524,568,000.00
  • Revenue This Year
  • ADPT $21.20
  • TPC $16.66
  • Revenue Next Year
  • ADPT $21.99
  • TPC $16.32
  • P/E Ratio
  • ADPT N/A
  • TPC N/A
  • Revenue Growth
  • ADPT 8.61
  • TPC 8.95
  • 52 Week Low
  • ADPT $2.99
  • TPC $14.50
  • 52 Week High
  • ADPT $10.28
  • TPC $34.55
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 57.82
  • TPC 80.72
  • Support Level
  • ADPT $8.38
  • TPC $22.44
  • Resistance Level
  • ADPT $9.51
  • TPC $23.36
  • Average True Range (ATR)
  • ADPT 0.66
  • TPC 1.51
  • MACD
  • ADPT 0.16
  • TPC 1.20
  • Stochastic Oscillator
  • ADPT 63.02
  • TPC 99.99

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: